Lv42
630 积分 2022-04-26 加入
Real world safety of bevacizumab in cancer patients: A systematic literature review of case reports
17天前
已完结
An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial
25天前
已完结
The next generation of immunotherapies for lung cancers
27天前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
27天前
已完结
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative non-small cell Lung cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data
1个月前
已完结
Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study
1个月前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
1个月前
已完结
Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysis
1个月前
已完结
Translating the m6A epitranscriptome for prostate cancer
1个月前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
1个月前
已完结
皖公网安备34019202002308
